- $184.86m
- $2.27bn
- $10.70bn
- 46
- 78
- 11
- 41
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 2.55 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -8.85% | ||
| Dividend Yield (f) | 0.08% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.03 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -17.57% | ||
| Return on Equity | -184.47% | ||
| Operating Margin | -4.11% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 8,480.18 | 9,785.32 | 9,955.48 | 10,333.97 | 10,700.88 | 2,769.58 | 2,604.08 | 3.04% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +93.56 | -79.52 | +69.3 | n/a | n/a | -8.85 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Accendra Health, Inc., formerly Owens & Minor, Inc., is a nationwide pure play home-based care platform. Its Patient Direct segment includes home healthcare divisions (Byram and Apria). The Patient Direct segment provides delivery of disposable medical supplies sold directly to patients and home health agencies and is a provider of integrated home healthcare equipment and related services in the United States. It offers a range of products and services for in-home care and delivery, including diabetes treatment, home respiratory therapy (including home oxygen and non-invasive ventilation services), and obstructive sleep apnea treatment (including continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services). Additionally, it supplies a wide range of other home medical equipment, patient care product lines including ostomy, wound care (including negative pressure wound therapy), urology, incontinence and other products and services.
Directors
- Mark Beck NEC (55)
- Edward Pesicka PRE (53)
- Andrew Long CFO (55)
- Christopher Lowery CEX (57)
- Jeffrey Jochims COO (53)
- Shana Neal CHO (55)
- Nicholas Pace EVP (50)
- Mark Zacur EVP (58)
- Michael Lowry SVP (59)
- Jonathan Leon SVP (54)
- Aster Angagaw IND (57)
- Gwendolyn Bingham IND (61)
- Robert Henkel IND (66)
- Stephen Klemash IND (60)
- Mark McGettrick IND (63)
- Last Annual
- December 31st, 2024
- Last Interim
- September 30th, 2025
- Incorporated
- December 20th, 1993
- Public Since
- March 17th, 1980
- No. of Shareholders
- 2,082
- No. of Employees
- 13,500
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
New York Stock Exchange- Shares in Issue
- 77,346,594
- Address
- 10900 Nuckols Road, Suite 400, GLEN ALLEN, 23060
- Web
- https://www.accendrahealth.com
- Phone
- +1 8042774304
- Contact
- Nick Teves
- Auditors
- KPMG LLP
Upcoming Events for ACH
Q4 2025 Accendra Health Inc Earnings Call
Q1 2026 Owens & Minor Inc Earnings Release
Owens & Minor Inc Annual Shareholders Meeting
Similar to ACH
Abbott Laboratories
New York Stock Exchange
Agilent Technologies
New York Stock Exchange
Alcon AG
New York Stock Exchange
Artivion
New York Stock Exchange
Avanos Medical
New York Stock Exchange
FAQ
What is the Accendra Health share price?
As of Today at 18:03 UTC, shares in Accendra Health are trading at $2.39. This share price information is delayed by 15 minutes.
How has the Accendra Health share price performed this year?
Shares in Accendra Health last closed at $2.39 and the price had moved by -72.37% over the past 365 days. In terms of relative price strength the Accendra Health share price has underperformed the S&P500 Index by -75.98% over the past year.
What are the analyst and broker recommendations for Accendra Health?
The overall consensus recommendation for Accendra Health is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Accendra Health dividend yield?
Accendra Health does not currently pay a dividend.
Does Accendra Health pay a dividend?
Accendra Health does not currently pay a dividend.
When does Accendra Health next pay dividends?
Accendra Health does not currently pay a dividend.
How do I buy Accendra Health shares?
To buy shares in Accendra Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Accendra Health?
As of the previous close price of $2.39, shares in Accendra Health had a market capitalisation of $184.86m.
Where are Accendra Health shares listed?
Here are the trading details for Accendra Health:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: ACH
What kind of share is Accendra Health?
Based on an overall assessment of its quality, value and momentum Accendra Health is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Accendra Health share price forecast for 2026?
The analyst consensus target price for shares in Accendra Health is $3.70. That is 54.81% above the last closing price of $2.39.
Analysts covering Accendra Health currently have a consensus Earnings Per Share (EPS) forecast of $1.03 for the next financial year.
Find out moreWhat is the trend in the Accendra Health share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Accendra Health. Over the past six months, its share price has underperformed the S&P500 Index by -69.01%.
As of the last closing price of $2.39, shares in Accendra Health were trading -53.9% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Accendra Health PE Ratio?
The Accendra Health PE ratio based on its reported earnings over the past 12 months is 2.55. The shares last closed at $2.39.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Accendra Health?
Accendra Health's management team is headed by:
- Mark Beck - NEC
- Edward Pesicka - PRE
- Andrew Long - CFO
- Christopher Lowery - CEX
- Jeffrey Jochims - COO
- Shana Neal - CHO
- Nicholas Pace - EVP
- Mark Zacur - EVP
- Michael Lowry - SVP
- Jonathan Leon - SVP
- Aster Angagaw - IND
- Gwendolyn Bingham - IND
- Robert Henkel - IND
- Stephen Klemash - IND
- Mark McGettrick - IND